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Background: Around one-third of breast cancers diagnosed every year in the UK are in women 
aged $70 years. However, there are currently no decision support interventions (DESIs) for older 
women who have a choice between primary endocrine therapy and surgery followed by adjuvant endo-
crine therapy (surgery+endocrine therapy), or who can choose whether or not to have chemotherapy 
following surgery. There is also little evidence-based guidance specifically on the management of 
these older patients. A large UK cohort study is currently underway to address this lack of evidence 
and to develop two DESIs to facilitate shared decision-making with older women about breast cancer 
treatments. Here, we present the development and initial testing of these two DESIs.
Methods: An initial prototype DESI was developed for the choice of primary endocrine therapy 
or surgery+endocrine therapy. Semi-structured interviews with healthy volunteers and patients 
explored DESI acceptability, usability, and utility. A framework approach was used for analysis. 
A second DESI for the choice of having chemotherapy or not was subsequently developed based 
on more focused development and testing.
Results: Participants (n=22, aged 75–94 years, 64% healthy volunteers, 36% patients) found the 
primary endocrine therapy / surgery+endocrine therapy DESI acceptable, and contributed to improved 
wording and illustrations to address misunderstandings. The chemotherapy DESI (tested with 14 
participants, aged 70–87 years, 57% healthy volunteers, 43% patients) was mostly understandable, 
however, suggestions for rewording sections were made. Most participants considered the DESIs 
helpful, but highlighted the importance of complementary discussions with clinicians. 
Conclusion: It was possible to use a template DESI to efficiently create a second prototype for a 
different treatment option (chemotherapy). Both DESIs were acceptable and considered helpful to 
support/augment consultations. Development of acceptable additional DESIs for similar target 
populations using simplified methods may be an efficient way to develop future DESIs. Further 
research is needed to test the effectiveness of the DESIs.
Keywords: patient decision aids, decision support, shared decision-making, breast cancer, 
older patients
Introduction
Every year about one-third of all new invasive breast cancer diagnoses in the UK are 
in women aged $70 years.1 Several patient decision aids exist to support women with 
breast cancer when making treatment decisions.2 However, to date, none has been 
developed for older women with estrogen receptor positive breast cancer who have a 
choice between primary endocrine therapy and surgery followed by adjuvant endocrine 
therapy (surgery+endocrine therapy), or for older women with high recurrence risk 
breast cancers (eg, HER2 positive, estrogen receptor negative, node positive) who 
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can choose whether or not to have chemotherapy following 
surgery. The current absence of decision support may, in 
part, reflect heterogeneous research and practice in managing 
breast cancer in older women.3–6
Research is needed to guide clinicians (this term is used 
to include all healthcare professionals) and patients about 
appropriate treatment for older women with estrogen receptor 
positive breast cancer and for older women with breast cancer 
with high recurrence risk. Surgery is the recommended treat-
ment for breast cancer for those who are fit enough, that is, 
unless precluded due to comorbidities.7,8 However, the ben-
efits of surgery vary in older women because life expectancy 
varies; there are some women for whom primary endocrine 
therapy may be as effective as surgery if they have a reduced 
life expectancy.9 For older women (70+), randomized trials 
have shown that while overall survival is not significantly 
different, primary endocrine therapy is less effective for local 
control9 and survival outcomes may be inferior on long-
term follow-up.10 The decision for older women is therefore 
preference sensitive. There is evidence for benefit of chemo-
therapy following surgery for older women with high-risk 
breast cancer.7,11 However, the trial evidence to underpin this 
is weak relative to other age groups, side effects are more 
common in older women,12 and the benefits of chemotherapy 
are less marked than in younger women. Consequently, rates 
of adjuvant chemotherapy use are highly variable across the 
UK in this older population.13
The Bridging the Age Gap in Breast Cancer program 
(National Institute for Health Research Programme Grants 
for Applied Research programme RP-PG-1209–10071, 
ISRCTN46099296)14 aims to provide guidance to clinicians 
about management and to provide decision support for 
patients. As part of this program of work, decision support 
interventions (DESIs) for two treatment choices (primary 
endocrine therapy or surgery+endocrine therapy and adjuvant 
chemotherapy or no chemotherapy) were developed. DESIs 
are tools that aim to support shared decision-making between 
clinicians and patients. The DESIs developed as part of this 
study each included a brief decision aid to be used within a 
consultation (a table of frequently asked questions with the 
answers for each treatment option), along with a booklet for 
patients which provided detailed information and a values 
clarification exercise (see “Methods” for more details) for use 
at home, with family or friends if desired. Guidelines from 
the International Patient Decision Aid Standards (IPDAS)15 
were consulted for advice on areas such as how to best present 
probabilities. An online algorithm to predict individual sur-
vival outcomes under each treatment option has also been 
developed (similar to Adjuvant! Online16 and PREDICT17)
for clinicians to use alongside the DESIs in clinical practice, 
which permits some tailoring of outcomes for the different 
options according to disease stage and type, age, and fitness. 
Development and usability testing of the brief decision aids 
and booklets are the focus of the present study.
Although it has been assumed that older cancer patients 
have stronger preferences for taking passive roles (doctor-
centered or paternalistic decision-making) in the decision-
making process than younger patients,18–20 recent evidence 
suggests that many older cancer patients do want to be 
involved in treatment decisions,20 including women with 
breast cancer.21–24 Preferences for decision-making style 
vary amongst older women with breast cancer treat-
ment decisions.22,23 In a questionnaire survey of women 
aged $75 years who had previously had a choice of primary 
endocrine therapy or surgery+endocrine therapy, preferences 
for patient-centered or doctor-centered decision-making were 
fairly even (39% and 38%, respectively) with slightly fewer 
preferring shared decision-making (24%).22 Most women 
discussing chemotherapy were found to prefer to be involved 
in decision-making.23 DESIs improve knowledge, accuracy 
of risk perception, and participation in decision-making as 
well as decreasing aspects of decisional conflict in decision-
making in older samples.25 They may therefore be particularly 
useful for clinicians and older women.
When developing DESIs it is important to use a trans-
parent and systematic approach.15 This includes an initial 
needs assessment and collating and summarizing the clinical 
evidence.15 Another integral part of DESI development is 
usability testing, before finalizing it for effectiveness test-
ing and implementation.26 This consists not only of check-
ing the DESI for clarity and understanding but also for its 
perceived usefulness by the target population and potential 
implementation barriers and facilitators. Field testing with 
patients facing the decision and their clinicians involved 
in shared decision-making about the decision has been 
included as a criterion of decision aid quality in the IPDAS 
instrument (IPDASi).26,27 The aims of the present study 
were to 1) develop two DESIs (primary endocrine therapy / 
surgery+endocrine therapy and chemotherapy) for older 
women with breast cancer treatment choices, with a more 
focused development and testing stage for the second DESI 
and 2) test the DESIs for usability, acceptability, and utility 
amongst older participants.
Methods
Prototype development
Approval for healthy volunteer involvement in the study 
was obtained from Cardiff University School of Medicine 
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Research Ethics Committee (reference 13/72) and Brighton 
and Sussex Medical School Research Governance and Ethics 
Committee (reference 15/111/HAR). Approval of the study 
protocol for patient involvement was obtained from the 
National Research Ethics Service London – Surrey Borders 
committee (reference 12/LO/1722) and the appropriate 
National Health Service Trust Research and Development 
Departments.
Primary endocrine therapy / 
surgery+endocrine therapy DESI
A schematic representation of DESI development is shown 
in Figure 1. The prototype DESI (brief decision aid plus 
booklet) was initially based on literature reviews and analyses 
of previous patient interviews conducted by members of the 
group9,10,18,21,24 and was developed using an iterative process. 
Literature reviews of the clinical evidence and patient infor-
mational needs and preferences were conducted. Existing 
breast cancer treatment decision aids were also reviewed. 
Data from patient interviews21,24 and a focus group with 
healthy female volunteers in a similar age group (not reported 
here) were collected and a summary of all the collated evi-
dence was produced. The Coping in Deliberation (CODE) 
framework28 was the theoretical basis for the DESI.24 The 
CODE framework highlights that cognitions, emotions, and 
coping are important in healthcare decisions throughout the 
deliberation process.28 The DESI therefore addressed cogni-
tive and emotional processes throughout deliberation as well 
as coping resources. The CODE framework was previously 
adapted for the decision about primary endocrine therapy or 
surgery+endocrine therapy in older women,24 and this was 
included within the overall evidence summary which guided 
the content of the DESI. An expert reference group consisting 
of 15 experts in the field (plus a chair from the study man-
agement group) reviewed the clinical evidence summary in 
detail (they also had the opportunity to comment on a draft 
prototype and the overall evidence summary). The overall 
summary was used as a basis for the DESI content. Guide-
lines from the Plain English Campaign29 were followed and 
editorial suggestions to improve the readability of the DESI 
were received from the Plain English Campaign29 before 
testing with patients (the final brief decision aid and booklet 
had “Crystal Marks” for clarity from the Plain English 
Campaign29). Feedback from healthcare professionals (n=3) 
who used the DESI during testing with patients was used 
to improve the DESI (not reported here). An outline of the 
DESI content is shown in Figure 2.
Chemotherapy DESI
A similar but more focused method was used to develop 
the prototype chemotherapy DESI. Content was based on 
analysis of patient interviews23 and a review of the published 
clinical evidence about chemotherapy use in older women 
by a small group of experts. The format and style (and some 
of the wording/headings/questions where appropriate) of 
this DESI were based on the primary endocrine therapy / 
surgery+endocrine therapy DESI due to similarity between 
the patient populations. An outline of the chemotherapy DESI 
content is shown in Figure 3.
Usability testing
Following initial development, both prototype DESIs (both 
brief decision aid and booklet for each decision) were tested 
for usability, acceptability, and utility using semi-structured 
Figure 1 Schematic representation of the primary endocrine therapy / surgery+ 
endocrine therapy DESI development process.
Note: Images reproduced with permission from the University of Sheffield.
Abbreviations: DESI, decision support intervention; FAQs, frequently asked questions.
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interviews (Supplementary material). To minimize burden 
among women diagnosed with breast cancer, preliminary 
testing was first conducted among healthy volunteers 
aged $70 years ($75 years for the primary endocrine 
therapy / surgery+endocrine therapy DESI). This was fol-
lowed by testing with patients who had made a breast cancer 
treatment decision in the last 12 months, before finally testing 
the DESI (primary endocrine therapy / surgery+endocrine 
therapy DESI only) with those currently facing the treatment 
decision. Modifications to the DESIs were made between 
the two phases based on the results and further changes to 
the primary endocrine therapy / surgery+endocrine therapy 
DESI were made following patient feedback.
sample recruitment
Volunteers
Female volunteers were recruited from a number of sources 
including breast cancer charities and local community groups 
(eg, older persons’ groups in churches and community centers). 
Emails and phone calls were made to various organizations and 
in some cases the researchers visited groups and either gave 
a presentation or had an informal discussion about the study. 
Figure 2 Primary endocrine therapy / surgery+endocrine therapy DESI content.
Note: Reproduced with permission from the University of Sheffield.
Abbreviation: Desi, decision support intervention.
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A snowball sampling method was used. Invitation packs 
(including invitation letter, information sheet, consent form, 
and prepaid envelope) were given to anyone interested.
Patients
Patients were recruited via four UK breast units: Cardiff, 
Doncaster, Sheffield, and Southampton. They were identified 
from other strands of the Bridging the Age Gap in Breast 
Cancer programme (having completed a form to register their 
interest) or from clinic records and multidisciplinary team 
meetings. Some patients who had already registered interest 
in the study were sent an invitation pack directly. Others were 
invited by a research nurse and/or their clinician.
Procedure
Completed consent forms were returned to the researcher, who 
then contacted the participants to answer any further ques-
tions about the study and arrange an interview. Participants 
were sent the relevant DESI along with a letter confirming 
their interview appointment. Semi-structured interviews were 
conducted at a place convenient to the participant (most in 
their home, one in a church, and six by telephone), and were 
audio-recorded if participants consented to this. Participants 
who used the DESI when they faced the decision of primary 
endocrine therapy or surgery+endocrine therapy and chose 
surgery were interviewed before surgery. The interview guide 
included the following topics: understanding of the content, 
layout, usefulness, and potential improvements of the DESI 
(Supplementary material).
Data analysis
Sections relevant to data analysis were transcribed. 
A framework30 approach was used to analyze the data. This 
included the following stages 1) familiarization of the data 
(both listening to the recordings and reading transcripts), 2) 
coding of the data (Table 1), 3) charting the data by each 
code, and 4) reviewing and summarizing each of the charted 
codes for the groups of participants. Data were initially coded 
by KL and 20% was double coded by HH or MB. Following 
discussions about discrepancies, all transcripts were recoded 
(KL). NVivo qualitative data analysis Software31 version 11 
was used to manage the data.
Figure 3 Chemotherapy DESI content.
Note: Reproduced with permission from the University of Sheffield.
Abbreviation: Desi, decision support intervention.
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Results
sample characteristics
Primary endocrine therapy / surgery+endocrine 
therapy DESI
Interviews were completed with 22 women: 14 were healthy 
volunteers, four were patients who had faced the decision in 
the last 12 months, and four were currently facing the deci-
sion when they first received the DESI. Women were aged 
between 75 and 94 years (median 82.5 years). Volunteers 
were from South Wales (n=9) and South West England (n=5). 
Patients were from South Wales (n=3), Wessex (n=3), and 
Yorkshire and the Humber (n=2). Of the eight patients, four 
were having primary endocrine therapy and four were due 
to have (currently facing the decision) or had undergone 
(previously faced the decision) surgery. Transcripts from 21 
participants were analyzed. One participant chose not to be 
recorded, therefore, interviewer’s notes were analyzed.
Chemotherapy DESI
Interviews were completed with 14 women: eight were 
healthy volunteers and six were patients who had faced the 
decision in the last 12 months. Participants’ ages ranged from 
70 to 87 years (median 74 years). Healthy volunteers from 
South Wales (n=3), South West England (n=1), and South 
England (n=4) were recruited and interviewed. Of the six 
patients, all of whom were from Yorkshire and the Humber, 
five had had chemotherapy and one had not.
Desi feedback
Results from the main analyses are presented in three sections 
below: primary endocrine therapy / surgery+endocrine 
therapy DESI content, chemotherapy DESI content, and 
DESI use/implementation (covering both DESIs). Sample 
quotes to demonstrate the findings are presented in Table 2 
and referred to in the text in parentheses. Each quote is fol-
lowed by a description of the participant characteristics as 
follows: DESI viewed, which element they are referring to, 
and which part of the testing they were involved with (see 
Table 1 footnote for details).
Primary endocrine therapy / surgery+endocrine 
therapy DESI content
Generally, the feedback was positive about the primary 
endocrine therapy / surgery+endocrine therapy DESI. Both 
the brief decision aid and booklet were understood and 
mostly clear (A). The brief decision aid was described as 
the “headlines” and the booklet containing more detailed 
backup information. Women thought that the DESI cov-
ered the information patients would want and most women 
thought the amount of information was appropriate. Some 
of the healthy volunteers felt that the booklet was quite long, 
but none said the amount should be reduced; rather, it was 
comprehensive. A mixture of views was given by volunteers 
about the size of the booklet, some liking the A4 size (user 
testing paper version) and others liking the idea of an A5 
booklet. The graphic design version of the booklet received 
generally positive feedback from patients in terms of color, 
size (A5 was standard and a large print A4 version was also 
available), and layout. The diagrams and pictures had mixed 
reviews in terms of both understanding and helpfulness (some 
thought redundant). A diagram showing lymph nodes was 
misinterpreted as cancer by one patient (who had previously 
faced the decision) and was thought quite frightening by two 
other patients, so was changed during field testing (before 
testing with patients currently facing the decision) (B). 
Table 1 interview transcript coding framework
Primary code Secondary code
Brief decision aid Layout/ease of use (usability)
Useful content (usability)
Understanding (accessibility)
information amount
Questions
improvements
Booklet Layout/ease of use (usability)
Useful content (usability)
Understanding (accessibility)
information amount
Questions
Values clarification exercise
Other sections
improvements
implementation Usefulness (utility)
Practicalities
Usagea
Other Personal experiencesb
cancer diagnosisb,c
Decisionb
Follow-up careb,c
Questionb
referenceb
Miscellaneousb
general comment on Desi
Notes: aPatients facing the decision only. bshows codes not used for presented 
analysis. cPatients only.
Abbreviations: Desi, decision support intervention.
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This new version of the diagram was understood. Natural 
frequencies in the text were understood by most volunteers, 
although two found them confusing. Pictograms were added 
in the field testing versions of the booklet and most, but not 
all, patients were positive about these.
Some information lacked clarity and/or caused confu-
sion to the volunteers. Examples include the information on 
recurrence not being comparable and for some the values 
clarification exercise – which included a table with each 
treatment option listed at the top of each column where 
Table 2 Example quotes for the main findings
Primary code Secondary code Example quotes Text 
reference
Primary endocrine therapy /  
surgery+endocrine therapy  
brief decision aid and  
booklet
Understanding “… it was really in layman’s terms, you didn’t have to know 
anything about medicine or medical matters, it was all put 
down to you in a very, you know, very straightforward way …” 
Desi-s-Bo-sFT
A
[Referring to diagram of cancer lump and lymph nodes] “It’s all 
over the flaming place isn’t it? Look at that, lymph node, gee by 
gum, yes that is pretty bad that. […] It grows away from the 
cancer doesn’t it, going to the nodes and into your arm? […] That 
makes it look as if it’s where the cancer is.” DESI-S-Bo-SFT
B
[Referring to the chances of the breast cancer coming back] 
“… its 20 in 100 women after 1 to 3 years in the hormone 
blocking. 10 in 100 –10% over the lifetime time so if a person 
wanted to know what would be my risks of getting it in the first 
few years of either treatment – if it’s possible to answer that …” 
Desi-s-Br-sUT
c
improvements “… is there a difference in how long i will live – does that mean 
if you don’t have treatment? […] no difference to what? […] 
that’s not very clear. […] there has to be an ‘if’ in it somewhere.” 
Interviewer: “yes so if – is there a difference in how long I will live 
if I take the tablets or if I […] have the surgery and the tablets.” 
Participant: “yes” DESI-S-Br-SUT
D
“ ‘Usually women notice the swelling because their arm feels 
heavier or rings and clothes seem’ […] Your clothes seem tighter, 
I wouldn’t have thought, your sleeves might (seem) tighter, but 
not all your clothes, surely.” DESI-S-Bo-SFT
e
Chemotherapy brief  
decision aid and booklet
Understanding “… I found page 5 in the booklet thoroughly confusing … because 
I felt it came in very early in the booklet and it, for a person, an 
older person to try to take in all that information, I found more 
confusing than …” DESI-C-Bo-CUT
F
“i found the numbers, the ratio of the numbers of me living 
longer … or even surviving … seemed very small … [separate 
quote] it’s been scare … a bit scare … it’s been frightening … 
reading, reading what your chances are … […] it looks as though 
I’ve got like a 1 in a 5 chance…” DESI-C-Bo-CFT
g
Layout “… it was nice to have photographs in and I thought they were 
perfectly alright. And 1 or 2 of them were quite nice, there’s a 
nice one on page 19, i was just looking at it now. You feel as if 
the nurse and the patient are very much on the same wave length 
that’s very nice and I think anything like that is, that’s particularly 
good.” DESI-C-Bo-CUT
h
improvements “I mean the other thing is you probably would have to have it in, 
in different languages wouldn’t you?” DESI-C-CFT
i
Primary endocrine therapy /  
surgery+endocrine therapy 
booklet
Values clarification exercise “I didn’t (look at) this page to be honest. I suppose it’s because I’d 
spoken to [name], that probably did that you see.” DESI-S-Bo-SFT
J
(Continued)
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participants could enter their preferences for that treatment 
(see Figure 4 for final version) – needed more explanation (C). 
These were reviewed by the development team and changes 
were made to the DESI as appropriate before field test-
ing. Similarly, volunteers suggested improvements such 
as rewording sentences, emphasizing particular pieces of 
information and adding details which were amended as seen 
appropriate (D). A number of questions were raised. Some 
questions raised by volunteers could be addressed within the 
DESI, others would be asked of a clinician. Patients asked 
general questions as well as requested clarifications and made 
suggestions for improvements (E).
Chemotherapy DESI content
The feedback on the chemotherapy DESI was also positive 
overall. Most women thought that it was understandable 
and included the things that patients would want to know. 
However, some healthy volunteers acknowledged that some 
people might need help going through it and one woman 
found the page about secondary breast cancer and what 
increases the risk of the cancer spreading (page 5) particu-
larly confusing (F). Despite changes, a few things were not 
understood by patients, with one not understanding about 
having trastuzumab and another struggling to understand 
the increased benefit of trastuzumab (but another woman 
felt that it clarified some people have trastuzumab alongside 
chemotherapy). One woman did not seem to understand the 
increase in benefit that chemotherapy offers; she interpreted 
the increase as the chance of survival (G).
Most liked the layout, describing it as well set out and 
they liked the photographs (H). However, one woman com-
mented that there were no women from ethnic minorities. 
The lack of ethnic minority photographs was deliberate 
because there are currently very few ethnic minority women 
in the $70 years age group in the UK,32 although this will 
change in the future as cohorts age. Some women felt the 
booklet was a bit repetitive but others felt that the repetition 
was appropriate and that all the information needed to be 
included, hence no changes were made. Patients thought the 
amount of information was about right. Some improvements 
were suggested by healthy volunteers (eg, emphasizing that not 
everyone will experience the side effects) and patients (eg, sup-
plying the information in different languages); however, 
few patients thought that any improvements were needed (I).
Table 2 (Continued)
Primary code Secondary code Example quotes Text 
reference
implementation Usefulness “… they can go home and look through the booklet, they can 
write down what they want to ask you because I think like when 
you go to the doctor you need to write down what you want to 
say because when you get there you’ve forgotten all what you 
wanted to say to them.” DESI-S-Bo-SUT
K
Interviewer: “How do you think women might find this if they did 
have breast cancer, when they were thinking about their decisions 
and treatments options?” Participant: “I think they would probably 
find it helpful but they’d need to have, it’s not helpful just on 
its own, it needs to have someone that you’re able to discuss it 
with.” DESI-C-Bo-CUT
l
“I wish, when they diagnosed me and everything, I wish I’d had a 
book like this to read.” DESI-S-Bo-SFT
M
“ ‘Is there an option, difference between the options in how long 
I will’ and I thought if I don’t have chemo I might die if it hasn’t all 
gone and reading that i thought well i have done the right thing, 
I’ve had chemo and if there’s anything there its, it’s made me 
decide...if I hadn’t have had it...[…]...I would have chosen to have 
it... [separate quote] … it help me cope because I knew I’d do, 
done right thing.” DESI-C-CFT
n
Usagea “My daughter wrote in it for me, things I had to remember to 
ask. […] I had to remember to ask them when I went before I 
decided. We sat and we discussed it.” DESI-S-Bo-SFT
O
Note: aPatients facing the decision only.
Abbreviations: Bo, booklet; Br, brief decision aid; CFT, chemotherapy field testing (patients); CUT, chemotherapy user testing (healthy volunteers); DESI, decision support 
intervention; DESI-C, chemotherapy DESI; DESI-S, primary endocrine therapy / surgery+endocrine therapy DESI; SFT, primary endocrine therapy / surgery+endocrine 
therapy field testing (patients); SUT, primary endocrine therapy / surgery+endocrine therapy user testing (healthy volunteers).
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Desi use/implementation
The DESIs were generally thought to be helpful. Women 
mentioned it being a good basis for questions (eg, as a 
prompt or reminder) and primary endocrine therapy / 
surgery+endocrine therapy patients talked about reading the 
information multiple times and finding it useful to be able to 
do this (K). Many healthy volunteers thought that it would 
be useful to take the DESI home to read, refer back to, and 
discuss with friends/family with a further discussion with 
clinicians afterward. Some mentioned that the information 
would be too much to take in at the diagnostic consultation 
or when initially hearing about treatments. They highlighted 
the importance of discussions with and advice from clini-
cians and expressed the view that some patients might need 
additional help with processing the information (L).
Many patients (previously facing the decision) thought 
that it could be helpful for others (including family members) 
(M). One found it very useful to confirm her chemotherapy 
decision, another felt she had learned more from the primary 
endocrine therapy / surgery+endocrine therapy brief decision 
aid than she had at diagnosis and another found receiving 
the information as part of the study useful (N). Two patients, 
however, felt the chemotherapy DESI was not for them 
(one preferring discussions with clinicians). Two patients 
found some of the information about treatment benefits 
and survival changes in the chemotherapy DESI upsetting 
and frightening (for one, possibly due to some misunder-
standing of what the natural frequencies were) (G). Two 
patients who were currently facing the primary endocrine 
therapy / surgery+endocrine therapy decision thought the 
DESI had helped to reinforce their initial decision leaning 
or to make the decision. Only one patient currently facing 
the decision (primary endocrine therapy / surgery+endocrine 
therapy) wrote in the values clarification exercise or “My 
questions” sections (O). The others felt no need to use it as 
they had already made their decision or spoken with their 
clinician (J).
Discussion
Two DESIs for older women with breast cancer treatment 
choices were developed based on the best available pub-
lished evidence and feedback from healthy volunteers and 
patients. A detailed and iterative process was used to develop 
the primary endocrine therapy / surgery+endocrine therapy 
DESI, both in terms of the initial prototype development 
(reviews of literature, theory based, new data collected, and 
Plain English Campaign29 involvement) and usability testing 
(with healthy volunteers and patients). It was possible to use 
the primary endocrine therapy / surgery+endocrine therapy 
DESI as a template upon which to base the chemotherapy 
DESI, hence a more efficient development and testing 
process was used for this second DESI. General feedback 
about language, colors, format, and size of the DESIs was 
transferable from one to the other. Feedback from partici-
pants about the DESIs included many positive comments, 
but areas of confusion were noted and possible changes 
were suggested. Potential amendments to the DESIs were 
discussed among the development team and changes were 
Figure 4 Values clarification exercise in primary endocrine therapy / surgery+endocrine therapy booklet.
Note: Reproduced with permission from the University of Sheffield.
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made where appropriate (eg, in the case where a diagram 
had been misinterpreted). While the DESIs were thought 
to be useful (for self or others), some patients preferred not 
to use the values clarification exercise as they had already 
spoken with their clinicians or made their decision. However, 
this section was retained in the DESIs, as helping patients 
consider and discuss their values and preferences about the 
options is a key element of decision support.15 Furthermore, 
the importance of discussions with clinicians was highlighted 
by women, and was reflected by the inclusion of signposting 
to this in the DESIs.
To our knowledge, no DESIs currently exist for older 
women making these two breast cancer treatment choices. 
The DESIs are currently being trialed within the Bridging 
the Age Gap in Breast Cancer study as part of an interven-
tion (which includes the booklets, brief decision aids, and an 
online algorithm to predict survival under different treatment 
options) to primarily assess their effects on quality of life.14 
Other measures of decision support are also being evaluated 
in the trial (eg, shared decision-making, decision regret, and 
knowledge).14 Another strength of this study is the detailed 
and systematic process used to develop the initial DESI, 
following IPDAS15 guidelines, and use of the first DESI as 
a template to develop the second DESI. The advantages of 
being able to develop a DESI more efficiently are important. 
Using a more efficient development method could save 
resources, both in terms of burden to participants (which may 
be particularly relevant in this older and sometimes frailer 
population) and in terms of developers’ time and funds. 
That a sample of older women was recruited to the present 
study, including some much older people (four participants 
were $90 years), is a further strength. Previously, difficulties 
in recruiting older women have been described, though these 
were within the context of clinical trials (and due to protocol 
restrictions and clinician reservation about treatments) rather 
than studies in general.33
We recognize the limitations of our development study. 
Firstly, the two groups of women likely to be eligible for 
the respective treatment options are different; those with a 
choice of primary endocrine therapy or surgery+endocrine 
therapy are likely to be frailer and older than those with 
a choice about chemotherapy. Older women may have 
different preferences for information style. Burton et al22 
found an inverse association between preference for written 
information and age even within a sample of older breast 
cancer patients ($75 years) offered a choice of primary 
endocrine therapy or surgery+endocrine therapy. Preferences 
elicited for the first DESI (which were based on women 
aged $75 years) may therefore not be completely transferable 
to the chemotherapy DESI. Secondly, due to time constraints 
of the program of work, patients currently facing the decision 
about chemotherapy were not included in the sample. Lastly, 
while the DESIs are based on the best clinical evidence 
available at the time, new survival outcome data for this 
older population are being collected as part of the Bridging 
the Age Gap in Breast Cancer study (ISRCTN46099296).14 
Not only will the DESIs therefore need updating when this 
is available, they will also need updating if new treatment 
options become available in the future.
Participants highlighted the need for interaction with 
clinicians, and the importance of clinicians’ shared decision-
making skills and attitudes has recently been highlighted.34 
Skills development for shared decision-making along with 
guidance on using the DESIs remains crucial for successful 
implementation in clinical practice.
Further research is needed in a larger sample to test the 
effectiveness of the DESIs in improving shared decision-
making for older women with breast cancer treatment 
choices (currently being done in the Bridging the Age Gap 
in Breast Cancer study, ISRCTN 4609929614). If they are 
effective, this will show that where patient populations 
are similar, DESIs for different treatment decisions can 
be developed based on the template of another DESI and 
on information already obtained from the patient popula-
tion, and then implemented. Resources saved (both time 
and funds) during the initial prototype and testing phases 
of development could then be directed toward supporting 
shared decision-making skills for clinicians and updating 
DESIs with new clinical evidence.
Conclusion
Two DESIs for older women with breast cancer have been 
successfully developed for two different treatment choices 
(primary endocrine therapy / surgery+endocrine therapy and 
chemotherapy / no chemotherapy). Using an iterative process 
of feedback and improvements, the DESIs were found to be 
acceptable and usable by patients. Having developed one 
DESI using a detailed and systematic process, it was pos-
sible to develop the second DESI for a different treatment 
choice more efficiently using information already captured 
for the initial DESI. Before developing the DESIs, there were 
none (to our knowledge) available for this group of older 
women having to make these particular treatment choices. 
With policy makers keen to promote shared decision-making 
and enhance patient-centered care, development of DESIs 
which inform patients about treatments and enable them to be 
 
Pa
tie
nt
 P
re
fe
re
nc
e 
an
d 
Ad
he
re
nc
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
3.
52
.3
0.
22
3 
on
 1
3-
Fe
b-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Patient Preference and Adherence 2019:13 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
141
Breast cancer decision support intervention development and testing
involved in treatment decisions is vital. An efficient process 
to develop these is therefore beneficial.
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Supplementary material
interview guide
•	 What do you think about the brief decision aid/
booklet?
•	 Is the brief decision aid/booklet easy to use and 
understand?
•	 What do you think about the questions listed on the left 
(brief decision aid only)?
•	 What do you think about the different sections of the 
booklet (booklet only)?
•	 Are there areas in the brief decision aid/booklet that need 
changing?
•	 Healthy volunteers: How useful do you think it could be 
for women who have a decision to make about treatment? 
Patients: How useful do you think it was/could have been 
when making your decision about treatment?
•	 Do you have any suggestions for improvement?
•	 Any other comments?
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